Ironwood Pharmaceuticals Shares Up 129% Hold Top Analyst Ranking, Q4 Results Due Feb. 26
Ironwood Pharmaceuticals shares rose 129.4% over the past 12 months and the stock holds a top analyst ranking. The company is scheduled to report fourth-quarter 2025 results on February 26, marking a key upcoming catalyst.
1. Ironwood Pharmaceuticals Performance and Outlook
Ironwood Pharmaceuticals has delivered a 129.4% total return over the trailing 12 months and currently holds a top analyst ranking. The company’s fourth-quarter 2025 earnings report is scheduled for February 26, which could serve as a significant trigger for further stock movement.
Related News
PERI
Perion Q1 Revenue Rises 1% as Outmax AI Spend Soars 300% and CTV Spend Jumps 68%
PERI•
NVDA
Nvidia Q2 Profit Jumps 200% with Revenue Up 85%
NVDA•
TJX
TJX Beats Q1 EPS by $0.20, Comps Up 6% and Spain Store Launch
TJX•
UPS
UPS MD-11 Crash After Engine Mount Inspections Extended to 29,260 Cycles
UPS•
TQQQ
ProShares 3x Nasdaq-100 ETF Gathers $31.3B, Hits 38.6% YTD Gain
TQQQ•
Sources
F